# Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Source: https://onco.cc/trials/nct06445972/  
OnCo record `nct06445972` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ramucirumab and Sacituzumab tirumotecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) is a phase 1/2 interventional study registered as NCT06445972 by Merck Sharp & Dohme LLC, with 210 participants planned, started 2024-08-07 and due to reach its primary completion in 2028-05-09. Interventions recorded: Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications and HER3-DXd.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06445972
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT06445972: https://clinicaltrials.gov/study/NCT06445972

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06445972.json